[Skip to Navigation]
Sign In
Views 416
Citations 0
Comment & Response
December 26, 2019

Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy

Author Affiliations
  • 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
JAMA Surg. 2020;155(3):267-268. doi:10.1001/jamasurg.2019.5089

To the Editor We have read with great interest the article by Hank et al.1 The authors indicated that neoadjuvant therapy (NAT) could reduce the rate of clinically relevant postoperative pancreatic fistula (CR-POPF). In addition, they demonstrated that CR-POPF is associated with a significant reduction in long-term survival for patients with pancreatic cancer with NAT.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words